US007244749B2

(12) **United States Patent**
Rath

(10) **Patent No.: US 7,244,749 B2**
(45) **Date of Patent: Jul. 17, 2007**

(54) **COMPOSITIONS AND METHODS FOR LOWERING PLASMA LIPOPROTEIN(A) AND RISK FACTORS OF CARDIOVASCULAR DISEASES**

(76) Inventor: **Matthias Rath**, Twelemport Cost 3 NL-7609 RG, Almelo (NL)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 346 days.

(21) Appl. No.: **10/765,236**

(22) Filed: **Jan. 26, 2004**

(65) **Prior Publication Data**

US 2004/0157895 A1 Aug. 12, 2004

Related U.S. Application Data

(62) Division of application No. 09/970,609, filed on Oct. 3, 2001, now Pat. No. 6,693,129.

(60) Provisional application No. 60/237,186, filed on Oct. 3, 2000.

(51) **Int. Cl.**

A61K 31/455	(2006.01)
A61K 31/401	(2006.01)
A61K 31/34	(2006.01)
A61K 31/195	(2006.01)
A61K 31/07	(2006.01)

(52) **U.S. Cl.** **514/355**; 514/356; 514/474; 514/562; 514/564; 514/725; 514/423; 514/458

(58) **Field of Classification Search** 514/474, 514/725, 458, 249, 251, 168; 424/655, 641, 424/630, 639, 640, 602, 614

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,009,265	A	2/1977	Howard
4,414,238	A	11/1983	Schmidl
4,657,866	A	4/1987	Kumar
4,891,220	A	1/1990	Donzis
5,108,767	A	4/1992	Mulchandani et al.
5,230,996	A	7/1993	Rath et al.
5,268,181	A	12/1993	Neill et al.
5,278,189	A	1/1994	Rath et al.
5,326,569	A	7/1994	Acosta et al.
5,332,579	A	7/1994	Umbdenstock
5,650,418	A	7/1997	Rath et al.
5,922,766	A	7/1999	Acosta et al.
5,962,517	A	10/1999	Murad
6,048,846	A	4/2000	Cochran
6,245,803	B1	6/2001	Acosta et al.
6,299,896	B1	10/2001	Cooper et al.
6,361,800	B1	3/2002	Cooper et al.
6,451,341	B1	9/2002	Slaga et al.
2002/0128309	A1	9/2002	Rath
2002/0173546	A1	11/2002	Rath
2003/0003162	A1	1/2003	Rath

FOREIGN PATENT DOCUMENTS

EP	0891771	A1	1/1999
EP	1068868	A2	1/2001
EP	1163904	A1	12/2001
EP	1195159	A1	10/2002
GB	2268871	A	1/1994

OTHER PUBLICATIONS

Kennedy, R. *Lipoprotein(a), Vascular Disease, and Vitamin C*. The Doctor's Medial Library, www.medical-library.net, Jan. 5, 1999.

Dardik et al., *A Quantitative Assay for the Non-Covalent Association Between Apolipoprotein(a) and Apolipoprotein B: An Alternative Measure of Lp(a) Assembly*. Journal of Lipid Research, vol. 41, 2000, esp. p. 1018, para 4.

Life Extension Mix Multivitamin, Product Information Brochure, www.iherb.com. 1997.

Multi Li Caps, Product Information Brochure, www.solgar.com, 1996.

Mega Vita-Min, Product Information Brochure, www.naturesbounty.com, 2000.

Vinson, Joe A, et al., *A Citrus Extract Plus Ascorbic Acid Decreases Lipids, Lipid Peroxides, Lipoprotein Oxidative Susceptibility, and Atherosclerosis in Hypercholesterolemic Hamsters*, J. Agric. Food Chem, vol. 46, pp. 1453-1459, 1998.

Giroux, Isabelle et al., *Role of dietary lysine, methionine, and arginine in the regulation of hypercholesterolemia in rabbits*, J. Nutr. Biochem., vol. 10, pp. 166-171, 1991.

Troger U. and Meyer F.P., British Medical Journal (1998) vol. 317, pp. 1069-1071.

Kostner, "HMG CoA reductase inhibitor lower LDL cholesterol without reducing Lp(a) levels" Circulation, Nov. 1989, vol. 80 No. 5, pp. 1313-1319.

Hegele, "The effect of genetic determinants of low density lipoprotein levels on lipoprotein (a)" Clin Invest Med, Apr. 1991, vol. 14 No. 2, pp. 146-152.

Watts, "Liprotein (a) as an Independent . . . common hypercholesterolaemia" J Clin Pathol, Mar. 1993, vol. 46 No. 3, pp. 267-270.

Olofinskaia, "Lipoprotein (A) in patients with coronary atherosclerosis" Kardiologiia, Oct. 1991, vol. 31 No. 10, pp. 36-38.

Primary Examiner—Brian Kwon
(74) *Attorney, Agent, or Firm*—Inhouse Co; Ali Kamarei, Esq.; Alexander Chen, Esq.

(57) **ABSTRACT**

The present invention provides compositions and methods for lowering plasma Lp(a) levels in humans. The present invention provides compositions and methods for lowering the risk factors for cardiovascular diseases. Moreover, this invention provides therapeutic alternatives to current pharmaceutical interventions for the lowering of cholesterol, LDL-cholesterol, triglycerides and other metabolic risk factors.

6 Claims, 2 Drawing Sheets